Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vandetanib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth
in different ways. Some block the ability of cancer cells to grow and spread. Others find
cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab and
vandetanib may also stop the growth of cancer cells by blocking blood flow to the cancer.
Giving vandetanib together with bevacizumab may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vandetanib and
bevacizumab in treating patients with advanced solid tumors or lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)